Plant TCM Composition for COVID-19 Treatment
Summary
The USPTO granted patent US12605420B2 to the National Research Institute of Chinese Medicine, Ministry of Health and Welfare, covering a traditional Chinese medicine composition for treating COVID-19 symptoms. The composition comprises ten herbal ingredients including Prepared Monkshood Daughter Root, Scutellaria Root, and Heartleaf Houttuynia Herb. The patent contains 8 claims and is classified under CPC A61K 36/714.
What changed
The USPTO granted patent US12605420B2 for a traditional Chinese medicine composition designed to treat moderate or severe COVID-19 symptoms. The composition contains ten herbal ingredients including Prepared Monkshood Daughter Root, Fragrant Solomonseal Rhizome, Indian Bread, Pinellia tuber, Oriental Wormwood Herb, Scutellaria Root, Mongolian Snakegourd Fruit, Magnolia Bark, Heartleaf Houttuynia Herb, and Baked Licorice Root and Rhizome.
The patent holder gains exclusive rights to manufacture and commercialize this specific herbal formulation for COVID-19 treatment in the United States. Healthcare researchers and pharmaceutical companies developing TCM-based therapeutics should review this patent landscape before entering the COVID-19 treatment space to assess Freedom to Operate considerations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of plant composition, traditional Chinese medicine composition in preparing medicine for treating COVID-19
Grant US12605420B2 Kind: B2 Apr 21, 2026
Assignee
National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Inventors
Yi-Chang Su, Wen-Hui Chiou, Yuh-Chiang Shen, Wen-Chi Wei, Keng-Chang Tsai, Chia-Ching Liao, Yu-Hwei Tseng, Chun-Tang Chiou, Yu-Chi Lin, Li-Hsiang Wang, Chien-Hsien Huang, Chia-Mo Lin, Chi-Kuei Lin, Yi-Chia Huang, Chien-Jung Lin, Jui-Shan Lin, Ya-Sung Yang, Chun-Hsiang Chiu, Shun-Ping Cheng, Hsien-Hwa Kuo, Wu-Pu Lin, Chen-Shien Lin, Bo-Cheng Lai, Yuan-Nian Hsu, Tsung-Lung Tsai, Wei-Chen Hsu, Tieng-Siong Fong, Yi-Wen Huang, Chia-I Tsai, Ya-Chen Yang, Ming-Che Tsai, Ming-Huei Cheng, Shih-Wei Huang
Abstract
The present invention relates to a method of treating moderate or severe symptoms of COVID-19 using a plant composition. The plant composition comprises Prepared Monkshood Daughter Root (Aconitum carmichaelii), Fragrant Solomonseal Rhizome (Polygonatum odoratum), Indian Bread (Poria cocos), Pinellia tuber (Pinellia ternata), Oriental Wormwood Herb (Artemisia scoparia), Scutellaria Root (Scutellaria baicalensis), Mongolian Snakegourd Fruit (Trichosanthes kirilowii), Magnolia Bark (Magnolia officinalis), Heartleaf Houttuynia Herb (Houttuynia cordata), and Baked Licorice Root and Rhizome (Glycyrrhiza glabra), which is used as a traditional Chinese medicine composition.
CPC Classifications
A61K 36/714
Filing Date
2022-10-19
Application No.
18047712
Claims
8
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.